Ocular Therapeutix, Inc. (NASDAQ:OCUL – Free Report) – Analysts at HC Wainwright issued their Q1 2027 earnings per share (EPS) estimates for Ocular Therapeutix in a research report issued on Thursday, June 18th. HC Wainwright analyst Y. Chen forecasts that the biopharmaceutical company will earn ($0.39) per share for the quarter. HC Wainwright has a “Buy” rating and a $25.00 price target on the stock. The consensus estimate for Ocular Therapeutix’s current full-year earnings is ($1.59) per share. HC Wainwright also issued estimates for Ocular Therapeutix’s Q3 2027 earnings at ($0.37) EPS.
Other research analysts have also issued reports about the stock. Needham & Company LLC reiterated a “buy” rating and set a $18.00 price objective on shares of Ocular Therapeutix in a report on Tuesday, May 5th. Robert W. Baird boosted their target price on shares of Ocular Therapeutix from $24.00 to $30.00 and gave the company an “outperform” rating in a report on Thursday. Weiss Ratings restated a “sell (d-)” rating on shares of Ocular Therapeutix in a report on Tuesday, April 21st. Royal Bank Of Canada reaffirmed an “outperform” rating and set a $30.00 price target on shares of Ocular Therapeutix in a research report on Wednesday, May 6th. Finally, William Blair reaffirmed an “outperform” rating on shares of Ocular Therapeutix in a research note on Monday, March 2nd. Twelve analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Ocular Therapeutix currently has an average rating of “Moderate Buy” and a consensus price target of $24.89.
Ocular Therapeutix Stock Down 2.2%
Shares of NASDAQ:OCUL opened at $9.43 on Friday. The company has a current ratio of 14.81, a quick ratio of 14.73 and a debt-to-equity ratio of 0.12. The firm has a market cap of $2.06 billion, a price-to-earnings ratio of -6.46 and a beta of 0.89. The stock’s 50-day moving average price is $8.97 and its two-hundred day moving average price is $9.92. Ocular Therapeutix has a 12-month low of $6.23 and a 12-month high of $16.44.
Institutional Trading of Ocular Therapeutix
A number of institutional investors and hedge funds have recently bought and sold shares of the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in Ocular Therapeutix by 5.8% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 93,619 shares of the biopharmaceutical company’s stock valued at $686,000 after buying an additional 5,156 shares in the last quarter. Caxton Associates LLP acquired a new stake in shares of Ocular Therapeutix in the first quarter worth $248,000. Creative Planning raised its stake in shares of Ocular Therapeutix by 21.5% in the 2nd quarter. Creative Planning now owns 21,410 shares of the biopharmaceutical company’s stock valued at $199,000 after acquiring an additional 3,791 shares during the period. JPMorgan Chase & Co. raised its stake in shares of Ocular Therapeutix by 110.8% in the 2nd quarter. JPMorgan Chase & Co. now owns 712,100 shares of the biopharmaceutical company’s stock valued at $6,608,000 after acquiring an additional 374,269 shares during the period. Finally, Prudential Financial Inc. raised its stake in shares of Ocular Therapeutix by 57.9% in the 2nd quarter. Prudential Financial Inc. now owns 18,700 shares of the biopharmaceutical company’s stock valued at $174,000 after acquiring an additional 6,855 shares during the period. Institutional investors and hedge funds own 59.21% of the company’s stock.
Insider Activity at Ocular Therapeutix
In other news, insider Pravin Dugel sold 21,156 shares of the firm’s stock in a transaction dated Tuesday, May 26th. The stock was sold at an average price of $8.20, for a total value of $173,479.20. Following the transaction, the insider directly owned 2,597,170 shares in the company, valued at $21,296,794. This trade represents a 0.81% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last quarter, insiders sold 28,999 shares of company stock valued at $237,792. Company insiders own 3.10% of the company’s stock.
About Ocular Therapeutix
Ocular Therapeutix, Inc is a biopharmaceutical company dedicated to the development of innovative therapies for diseases and conditions of the eye. Founded in 2011 and headquartered in Bedford, Massachusetts, the company focuses on sustained-release drug delivery platforms designed to address key unmet needs in ophthalmology. Its proprietary hydrogel-based inserts and sealants aim to improve patient compliance and outcomes by providing controlled release of active pharmaceutical ingredients directly to ocular tissues.
The company’s flagship product, DEXTENZA®, is a preservative-free, sustained-release dexamethasone intracanalicular insert approved by the U.S.
See Also
- Five stocks we like better than Ocular Therapeutix
- Credo Technologies Accelerates AI—Its Stock Price Will Follow
- Qualcomm Goes All-In: The $10B Bet to Crush NVIDIA
- Jabil Just Gave Investors a Stronger Reason to Buy the Dip
- CarMax In Reverse? Why You Should Buy Now Before the Big Catalysts Emerge
Receive News & Ratings for Ocular Therapeutix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocular Therapeutix and related companies with MarketBeat.com's FREE daily email newsletter.
